Cannabis & Wellness

The men's supplement industry is shifting from pure performance to holistic vitality. A new launch reveals the economic and scientific forces driving this change.

A Maine edibles brand is launching nationwide, but the real story is its strategic navigation of legal gray areas and its debut at the Food & Wine Classic.

Swiss brand NIANCE is moving beyond creams to build a global ecosystem of longevity clinics. It's a high-stakes bet on science in a trillion-dollar market.

Perspective Therapeutics is testing a potent alpha-particle therapy for meningioma, the most common brain tumor, offering a new option where surgery fails.

A call for research on vaccine side effects exposes a deeper crisis: the collapse of public trust in science. Can rigorous data heal a polarized nation?

As Rise Therapeutics advances its oral drug R-2487, it’s not just developing another pill. It’s testing a radical new idea: resetting the immune system.

A burgeoning market for cervical dystonia is set for disruption. A pipeline of novel therapies, including oral options, promises to address unmet patient needs.

As the old AYR Wellness liquidates, its key assets are reborn under creditor control. A forensic look at the deal, the debt, and what it signals for the industry.

A breakthrough in cardiac fibrosis treatment reveals more than a new drug; it signals a systemic shift. How AI and human 'organoids' are making animal models obsolete.

New preclinical data shows RTY-406 could be a first-in-class therapy for PSC, a progressive liver disease with no effective treatments.

ITG Brands acquires innovator Black Buffalo for $150M, diversifying beyond nicotine pouches to capture a new segment of smokeless alternative users.

Vanda Pharmaceuticals' rare disease drug gets a key designation in Japan, unlocking major incentives and promising a new treatment for a severe skin disease.

A new report reveals Europe's medically-focused cannabis market is finally waking, creating a new global blueprint but also intense competition and price wars.

MBX Biosciences prepares for the Jefferies conference, with investors eyeing updates on its late-stage hypoparathyroidism drug and promising obesity portfolio.

Cannabis giant Curaleaf is rolling the dice with a reverse stock split, aiming for a coveted spot on a major U.S. exchange ahead of federal rescheduling.

French biotech TreeFrog Therapeutics isn't just replacing cells; it's implanting pre-wired networks. Their novel 3D microtissue shows faster, more extensive brain repair.

MedX Holdings rebrands to Dazed Inc., launching a multi-city expansion and new coffee line to capitalize on cannabis's landmark move to Schedule III.

At SLAS 2026, MGI Tech unveiled intelligent platforms for proteomics and clinical automation, signaling a major push to accelerate scientific discovery.

Strong glaucoma sales and disciplined spending helped Iridex narrow its quarterly loss, signaling resilience despite retina segment woes and global headwinds.

A top scientific honor for Dr. Mariano Garcia-Blanco validates a new approach to autoimmune disease, targeting a genetic trait in 50% of the population.